Partnerships, Licensing, Investments and M&A Deals and Trends for January 2020 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2020 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deal Values in Pharmaceutical and Healthcare Industry Has Decreased in January 2020 9

2.1. Pharmaceuticals & Healthcare, Deals Summary, January 2020 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2020 13

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, January 2020 14

3.2.1. Nurix Therapeutics Enters into Agreement with Sanofi 15

3.2.2. Merck Enters into Licensing Agreement with Taiho Pharma and Astex Pharma 15

3.2.3. Incyte to Enter into Licensing Agreement with MorphoSys 16

3.2.4. Pharmaceutical Product Development (PPD) Raises USD1.62 Billion in IPO of Shares 16

3.2.5. Roche Enters into Licensing Agreement with Amunix Pharma 17

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2020 18

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2020 19

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, January 2020 20

4.1.1. Top M&A Deals in January 2020 21

4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2019 – January 2020 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2020 23

4.2.1. Top Equity Offering Deals in January 2020 24

4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2019 – January 2020 25

4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2020 27

4.3.1. Top PE/VC Deals in January 2020 28

4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2020 29

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2020 31

4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2019–January 2020 33

4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2019–January 2020 34

4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2020 35

4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2019 – January 2020 37

4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2020 39

4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2020 40

4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 41

4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2019 – January 2020 43

4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2019 – January 2020 44

4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 46

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2020 48

5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2020 48

5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2020 50

5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2019 – January 2020 52

5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2019 – January 2020 54

5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2019 – January 2020 56

5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2019 – January 2020 59

5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2020 60

5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2020 61

5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2020 62

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63

6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2020 63

6.1.1. Oncology – Deals of the Month 64

6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2020 67

6.2.1. Central Nervous System – Deals of the Month 68

6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2020 70

6.3.1. Infectious Diseases – Deals of the Month 71

6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2020 73

6.4.1. Cardiovascular – Deals of the Month 74

6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2020 76

6.5.1. Immunology – Deal of the Month 77

6.6. Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, January 2020 79

6.6.1. Metabolic – Deals of the Month 80

6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, January 2020 81

6.7.1. Gastrointestinal – Deals of the Month 82

7. Deal Summary by Geography 83

7.1. Pharmaceuticals & Healthcare, North America Deals, January 2020 83

7.1.1. North America – Deals of the Month 84

7.2. Pharmaceuticals & Healthcare, Europe, Deals, January 2020 87

7.2.1. Europe – Deals of the Month 88

7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2020 90

7.3.1. Asia-Pacific – Deals of the Month 91

7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2020 93

7.4.1. Rest of the World – Deals of the Month 94

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95

8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2019 – January 2020 95

8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2019 – January 2020 97

9. Further Information 99

9.1. Methodology 99

9.2. About GlobalData 100

9.3. Contact Us 100

9.4. Disclosure information 100

9.5. Disclaimer 100

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2020 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2020 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2020 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2019 – January 2020 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2020 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2020 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2019 – January 2020 29

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2020 32

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 33

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2019 – January 2020 34

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 35

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 38

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 39

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2020 40

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 42

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2019 – January 2020 45

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2019 – January 2020 47

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 49

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 51

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 53

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2020 55

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2019 – January 2020 58

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2020 60

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2020 60

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2020 61

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2020 62

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 64

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 68

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 71

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 74

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 77

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 80

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 82

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 84

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 88

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 91

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 94

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 96

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 98

List of Figures

1.2. List of Figures

Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, January 2020 9

Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, August 2019 – January 2020 10

Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, January 2020 11

Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, January 2020 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2020 18

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2020 19

Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2019 – January 2020 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 25

Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 27

Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2019 – January 2020 29

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2020 31

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2020 32

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 33

Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 39

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 41

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2019 – January 2020 43

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2019 – January 2020 44

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 46

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 48

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 50

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 52

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2019 – January 2020 54

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2019 – January 2020 56

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2019 – January 2020 57

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2020 59

Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 63

Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 67

Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 70

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 73

Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 76

Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 79

Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 81

Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 83

Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 87

Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 90

Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 93

Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 95

Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2019 – January 2020 97

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports